Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $122.20 · Expires 2025-03-18 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 3,859 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1: The option fully vested on February 2, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $263.20 · Expires 2026-03-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 1,218 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3: The option fully vested on January 1, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.80 · Expires 2026-09-30 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 4,200 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F4: The option fully vested on September 30, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.00 · Expires 2027-03-06 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 1,750 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F5: The option fully vested on January 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.40 · Expires 2028-03-06 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Disposition to issuer · Disposed 4,509 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6: The option fully vested on January 1, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.40 · Expires 2029-03-04 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-07-01 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F7: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.31 · Expires 2030-02-25 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-07-01 · Disposition to issuer · Disposed 94,113 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-07-01 · Disposition to issuer · Disposed 49,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F10: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-07-01 · Disposition to issuer · Disposed 5,887 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F11: The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F12: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-07-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F13: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vested on February 2, 2019.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
F3: The option fully vested on January 1, 2020.
F4: The option fully vested on September 30, 2019.
F5: The option fully vested on January 1, 2021.
F6: The option fully vested on January 1, 2022.
F7: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
F8: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F10: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
F11: The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F12: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
F13: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001554591-26-000002 · form4-06092026_080605.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 21:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001554591-25-000004 · form4-12292025_091244.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-12-23 F1 · derivative.exercise_date: The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:10 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-25-016466 · form4-06102025_080630.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 28,959 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001415889-24-021089 · form4-08122024_080817.xml · derivative · entry 2 Jagpal Sukhi · CIK 0001554591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,959 Underlying: Common Stock · 28,959 shares Expires 2034-08-08 F2 · derivative.exercise_date: The option vests as to 10.07% of the total award monthly beginning on September 8, 2024 through May 8, 2025, and 9.38% shall vest on June 6, 2025, with 100% of the award being vested and exercisable on the date of the issuer's 2025 annual meeting of its stockholders, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001415889-24-021089 · form4-08122024_080817.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: The option vests as to 2.778% of the total award monthly, beginning on September 8, 2024, with 100% of the award being vested and exercisable on August 8, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 11 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-03-14 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F13 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.73 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 10 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-03-15 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F12 · derivative.exercise_date: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 5,887 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 9 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,887 shares Expires 2030-08-12 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F11 · derivative.exercise_date: The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 8 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires 2030-08-12 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F10 · derivative.exercise_date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 94,113 | $0.00 Strike: $13.31 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 7 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,113 shares Expires 2030-02-25 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8 · derivative.exercise_date: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $78.40 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 6 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 4,509 | $0.00 Strike: $94.40 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 5 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,509 shares Expires 2028-03-06 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6 · derivative.exercise_date: The option fully vested on January 1, 2022. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $58.00 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 4 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2027-03-06 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F5 · derivative.exercise_date: The option fully vested on January 1, 2021. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 4,200 | $0.00 Strike: $72.80 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 3 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,200 shares Expires 2026-09-30 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F4 · derivative.exercise_date: The option fully vested on September 30, 2019. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 1,218 | $0.00 Strike: $263.20 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 2 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,218 shares Expires 2026-03-08 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3 · derivative.exercise_date: The option fully vested on January 1, 2020. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 3,859 | $0.00 Strike: $122.20 | $0.00 |
DisclosureSEC source: 0001209191-22-040271 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,859 shares Expires 2025-03-18 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1 · derivative.exercise_date: The option fully vested on February 2, 2019. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-037841 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 16:47 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-22-018490 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 28, 2022 Filed Jan 28, 2022 18:31 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005480 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:14 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.73 | $0.00 |
DisclosureSEC source: 0001209191-21-021619 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 12, 2020 Filed Aug 12, 2020 21:36 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 5,887 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-046501 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,887 Underlying: Common Stock · 5,887 shares Expires 2030-08-12 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 16:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 94,113 | $0.00 Strike: $13.31 | $0.00 |
DisclosureSEC source: 0001209191-20-013406 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,113 Underlying: Common Stock · 94,113 shares Expires 2030-02-25 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 17:28 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-19-016740 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-03-04 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 17:55 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 180,360 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-18-017780 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,360 Underlying: Common Stock · 180,360 shares Expires 2028-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-17-019362 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:10 UTC | Sierra Oncology, Inc. DNAI · Entity 125698 | GrantStock Option (right to buy) · Derivative | 168,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-16-144436 · doc4.xml · derivative · entry 1 Jagpal Sukhi · CIK 0001554591 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2026-09-30 F1 · derivative.exercise_date: The option vests as to 2.7778% of the total shares monthly, beginning on October 30, 2016, with 100% of the total shares vested and exercisable on September 30, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.